Complete Filing Data
Anbio Biotechnology reported Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents of $11.76 million for FY2024.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Anbio Biotechnology did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue * | $8.2M | $6.7M | $23.5M |
| Selling General And Administrative Expense | $3.4M | $1.3M | $2.2M |
| Research And Development Expense | $454.2K | $134.7K | $200.0K |
| Other Nonoperating Income | $19.5K | $8.0K | $43.6K |
| Operating Income Loss | $2.0M | $2.0M | $10.2M |
| Operating Expenses | $3.9M | $1.4M | $2.4M |
| Nonoperating Income Expense | $377.5K | $292.8K | -$184.4K |
| Net Income Loss | $2.4M | $2.3M | $10.0M |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | $2.4M | $2.3M | $10.0M |
| Gross Profit | $5.9M | $3.4M | $12.6M |
| Cost Of Revenue | $2.3M | $3.4M | $11.0M |
| Interest Expense Nonoperating | $8.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $11.8M | $9.7M | $7.1M | $4.2M |
| Stockholders Equity | $17.2M | $14.8M | $12.5M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $2.1M | $2.6M | $2.9M | |
| Retained Earnings Accumulated Deficit | $17.2M | $14.8M | ||
| Prepaid Expense And Other Assets Current | $25.6K | $403.9K | ||
| Other Liabilities Current | $105.0K | $165.9K | ||
| Operating Lease Right Of Use Asset Amortization Expense | $12.1K | $6.3K | ||
| Liabilities Current | $1.7M | $993.1K | ||
| Liabilities And Stockholders Equity | $18.9M | $15.8M | ||
| Liabilities | $1.7M | $993.1K | ||
| Deferred Costs | $387.4K | $42.8K | ||
| Cash And Cash Equivalents At Carrying Value | $11.8M | $9.7M | ||
| Assets Current | $18.5M | $15.7M | ||
| Assets | $18.9M | $15.8M | ||
| Additional Paid In Capital Common Stock | $3.8K | $3.8K | ||
| Accounts Receivable Net Current | $1.1M | $1.9M | ||
| Accounts Payable Current | $1.6M | $827.2K | ||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | $18.3K | |||
| Other Receivable After Allowance For Credit Loss Noncurrent | $18.0K | |||
| Deposits Assets Noncurrent | $1.3K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Proceeds From Sale And Maturity Of Marketable Securities | $35.8M | $20.3M | $14.6M |
| Payments To Acquire Marketable Securities | $35.5M | $18.5M | $16.1M |
| Net Cash Provided By Used In Operating Activities | $2.1M | $898.4K | $4.4M |
| Net Cash Provided By Used In Investing Activities | $337.1K | $1.7M | -$1.5M |
| Increase Decrease In Prepaid Expenses Other | $1.9M | -$1.0M | $4.8M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$396.3K | $306.0K | $81.0K |
| Increase Decrease In Other Current Liabilities | -$60.9K | $162.7K | -$486.8K |
| Increase Decrease In Deposit Other Assets | -$1.3K | -$1.7K | $3.0K |
| Increase Decrease In Accounts Receivable | -$820.2K | $1.9M | -$717.5K |
| Increase Decrease In Accounts Payable | $798.1K | -$580.9K | -$481.8K |
| Payments Of Stock Issuance Costs | $344.6K | $42.8K | |
| Net Cash Provided By Used In Financing Activities | -$344.6K | -$42.8K | |
| Increase Decrease In Inventories | -$353.9K | $353.9K | |
| Increase Decrease In Operating Lease Liability | -$18.3K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 42.3M | 21.4M | 100.00 |
| Earnings Per Share Diluted | $0.06 | $0.11 | $100,112.00 |
| Earnings Per Share Basic | $0.06 | $0.11 | $100,112.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Realized Investment Gains Losses | $337.1K | $163.4K | $38.9K |
| Investment Income Interest | $337.5K | $165.3K | $42.2K |
| Foreign Currency Transaction Gain Loss Before Tax | $20.5K | $119.4K | -$262.2K |
| Prepaid Expense Current | $5.7M | $3.8M | |
| Stock Issued During Period Value Other | $10.0K | ||
| Stock Issued During Period Value New Issues | $8.0K |
Most recent annual filing with the SEC: April 28, 2025
Data sourced from SEC EDGAR public filings as of August 5, 2026.